These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 9950200)
1. Outcomes and prognostic factors of Chinese children with acute lymphoblastic leukemia in Hong Kong: preliminary results. Shing MM; Li CK; Chik KW; Lam TK; Lai HD; Ng MH; Cheung AY; Yuen PM Med Pediatr Oncol; 1999 Feb; 32(2):117-23. PubMed ID: 9950200 [TBL] [Abstract][Full Text] [Related]
2. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia. Hann I; Vora A; Richards S; Hill F; Gibson B; Lilleyman J; Kinsey S; Mitchell C; Eden OB Leukemia; 2000 Mar; 14(3):356-63. PubMed ID: 10720126 [TBL] [Abstract][Full Text] [Related]
3. Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Medical Research Council Working Party on Childhood Leukaemia. Richards S; Burrett J; Hann I; Chessells J; Hill F; Bailey C Leukemia; 1998 Jul; 12(7):1031-6. PubMed ID: 9665186 [TBL] [Abstract][Full Text] [Related]
4. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S; Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289 [TBL] [Abstract][Full Text] [Related]
5. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Eden OB; Lilleyman JS; Richards S; Shaw MP; Peto J Br J Haematol; 1991 Jun; 78(2):187-96. PubMed ID: 2064956 [TBL] [Abstract][Full Text] [Related]
6. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Chessells JM; Bailey C; Richards SM Lancet; 1995 Jan; 345(8943):143-8. PubMed ID: 7823668 [TBL] [Abstract][Full Text] [Related]
7. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991 [TBL] [Abstract][Full Text] [Related]
8. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party. Hann IM; Richards SM; Eden OB; Hill FG Leukemia; 1998 Aug; 12(8):1249-55. PubMed ID: 9697880 [TBL] [Abstract][Full Text] [Related]
9. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy. Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546 [TBL] [Abstract][Full Text] [Related]
11. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119 [TBL] [Abstract][Full Text] [Related]
12. Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study. Dujua AC; Hernandez FG J Pediatr Hematol Oncol; 2017 Apr; 39(3):e116-e123. PubMed ID: 28085747 [TBL] [Abstract][Full Text] [Related]
13. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan. Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507 [TBL] [Abstract][Full Text] [Related]
14. Results of Medical Research Council trial UKALL IX in acute lymphoblastic leukaemia in adults: report from the Medical Research Council Working Party on Adult Leukaemia. Durrant IJ; Richards SM Br J Haematol; 1993 Sep; 85(1):84-92. PubMed ID: 8251413 [TBL] [Abstract][Full Text] [Related]
15. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699 [TBL] [Abstract][Full Text] [Related]
16. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J; J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125 [TBL] [Abstract][Full Text] [Related]
17. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416 [TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group. Matsuzaki A; Ishii E; Nagatoshi Y; Eguchi H; Koga H; Yanai F; Inada H; Nibu K; Tamai Y; Akiyoshi K; Nakayama H; Hara T; Take H; Miyazaki S; Okamura J Int J Hematol; 2001 Apr; 73(3):369-77. PubMed ID: 11345205 [TBL] [Abstract][Full Text] [Related]
19. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Roy A; Bradburn M; Moorman AV; Burrett J; Love S; Kinsey SE; Mitchell C; Vora A; Eden T; Lilleyman JS; Hann I; Saha V; Br J Haematol; 2005 Apr; 129(1):35-44. PubMed ID: 15801953 [TBL] [Abstract][Full Text] [Related]
20. Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. Chessells JM; Harrison G; Richards SM; Gibson BE; Bailey CC; Hill FG; Hann IM; Br J Haematol; 2002 Aug; 118(2):445-55. PubMed ID: 12139731 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]